A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial

Autor:	Joyce M. van Dodewaard-de Jong, Haiko Bloemendal, John M. H. de Klerk, Daniela E Oprea-Lager, Otto S. Hoekstra, H Pieter van den Berg, Maartje Los, Aart Beeker, Joe M. O'Sullivan, Henk M.W. Verheul, Alfonsus Johannes Maria van den Eertwegh
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry organic chemicals 030232 urology & nephrology Phases of clinical research Castration resistant urologic and male genital diseases medicine.disease 03 medical and health sciences Prostate cancer 0302 clinical medicine Docetaxel 030220 oncology & carcinogenesis Internal medicine medicine First line chemotherapy business therapeutics neoplasms medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:5081-5081
ISSN:	1527-7755 0732-183X
Popis:	5081Background: Docetaxel is first line chemotherapy in CRPC. Re-188 is a beta-emitting radiopharmaceutical that targets bone metastases. We investigated whether treatment with docetaxel plus Re-18...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4a25c4a96d3c796dad7f60d64ac3760e https://doi.org/10.1200/jco.2016.34.15_suppl.5081 Zobrazit plný text záznamu